Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues

Japanese Journal of Cancer Research

Volumn 90, Issue 7, 1999, Pages 758-764

  Ogino, Mitsuharu ^a   Hisatomi, Hisashi ^b   Murata, Minoru ^c   Hanazono, Makoto ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SRL INC   (Japan)

^c Tsukuba ARL   (Japan)

Author keywords

Fluorescence based telomeric repeat amplification protocol; Indomethacin; Prostaglandin E2; Telomerase activity

Indexed keywords

INDOMETACIN; PROSTAGLANDIN E2; TELOMERASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOMA; CANCER CELL CULTURE; CANCER INHIBITION; COLON; COLON TUMOR; CONTROLLED STUDY; DRUG MECHANISM; ENZYME REPRESSION; FIBROSARCOMA; LIVER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; TESTIS;

EID: 0032795309     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00812.x     Document Type: Article

References (35)

1. Cross, D. S., Platt, J. L., Juhn, S. K., Bach, F. H. and Adams, G. L. Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck. Arch. Otolaryngol. Head Neck Surg., 118, 526-528 (1992).
2. Maca, R. D., Burford, J. G. and Taylor, R. T. The effects of indomethacin and interleukin-2 on the proliferation of lymphocytes from patients with lung cancer. J. Clin. Immunol., 5, 158-165 (1985).
3. Blitzer, A. and Huang, C. C. The effect of indomethacin on the growth of epidermoid carcinoma of the palate in rats. Arch. Otolaryngol., 109, 719-723 (1983).
4. Sato, M., Narisawa, T., Sano, T., Takahashi, T. and Goto, A. Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. J. Cancer Res. Clin. Oncol., 106, 21-26 (1983).
5. 1 mice. Int. J. Clin. Oncol., 3, 176-181 (1998).
6. Ogino, M., Hisatomi, H. and Hanazono, M. Effectiveness of indomethacin as an antitumor agent in Colon 26-bearing conventional and nude mice, and telomerase activity in the tumors. Exp. Anim., 48, 15-21 (1999).
7. n, present at the telomeres of human chromosomes. Proc. Natl. Acad. Sci. USA, 85, 6622-6626 (1988).
8. Counter, C. M., Avillion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B. and Bacchetti, S. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J., 11, 1921-1929 (1992).
9. Hiyama, E., Yokoyama, T., Tatsumoto, N., Hiyama, K., Imamura, Y., Murakami, Y., Kodama, T., Piaztyszek, M. A., Shay, J. W. and Matsuura, Y. Telomerase activity in gastric cancer. Cancer Res., 55, 3258-3262 (1995).
10. 1 mice. Proc. Jpn. Acad., 73(Ser. B), 150-153 (1997).
11. Kido, A., Tsujiuchi, T., Morishita, T., Tsutsumi, M., Takahama, M., Miyauchi, Y., Mii, Y., Tamai, S. and Konishi, Y. Telomerase activity correlates with growth of transplantable osteosarcomas in rats treated with cis-diammine dichloro-platinum or the angiogenesis inhibitor AGM-1470. Jpn. J. Cancer Res., 89, 1074-1081 (1998).
12. Ogino, M. and Hanazono, M. Indomethacin preferentially augments 5-fluorouracil cytotoxicity in Colon 26 tumors by increasing the intracellular inflow of 5-fluorouracil. Int. J. Clin. Oncol., 4, 22-25 (1999).
13. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1984).
14. Ogino, M., Abe, Y., Okahara, T. and Jimbo, T. Comparison of plasma prostanoid levels in the human cord artery in normal and fetal distressed deliveries. Endocrinol. Jpn., 33, 75-80 (1986).
15. Lowry, O. H., Rosebrough, N. H., Farr, A. L. and Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193, 265-275 (1951).
16. Hisatomi, H., Nagao, K. and Komatsu, H. Quantification of telomerase activity in human liver tissues by fluorescence-based TRAP analysis. Hepatol. Res., 7, 36-42 (1997).
17. Van Laar, J. A., Rustum, Y. M., Van der Wilt, C. L., Smid, K., Kuiper, C. M., Pinedo, H. M. and Peters, G. J. Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinoma. Cancer Chemother. Pharmacol., 39, 79-89 (1996).
18. Ogino, M. Indomethacin augmented antitumor activity of 5-fluorouracil in Meth-A induced mice. Int. J. Clin. Oncol., 1, 75-79 (1996).
19. Yamashita, Y., Hirai, T., Mukaida, H., Iwata, T., Tetsuya, Y. and Hoon, H. J. A new experimental trial using heating every 24 hours for local hyperthermia therapy with bleomycin in vivo. Jpn. J. Surg., 20, 671-676 (1990).
20. 31P-MR spectroscopy in experimental tumors following radiotherapy combined with 5-fluorouracil compound (UFT). Tohoku J. Exp. Med., 169, 215-223 (1993).
21. Alván, G., Orme, M., Bertilsson, L., Ekstrand, R. and Palmer, L. Pharmacokinetics of indomethacin. Clin. Pharmacol. Ther., 18, 364-373 (1975).
22. Maca, R. D. Inhibition of the growth of Lewis lung carcinoma by indomethacin in conventional, nude, and beige mice. J. Biol. Response Mod., 7, 568-580 (1988).
23. 2 induction of suppressor T lymphocytes. J. Immunol., 132, 1851-1857 (1984).
24. Mori, H., Hanabayashi, T., Yamada, Y. and Tamaya, T. Decrease in interferone-γ production by peripheral blood mononuclear cells in patients with uterine cervical cancer. J. Clin. Immunol., 10, 45-51 (1990).
25. 2 production by monocyte is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer. Cancer, 72, 491-501 (1993).
26. Lala, P. K., Parhar, R. S. and Singh, P. Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor bearing mice and prevents tumor metastasis. Cell Immunol., 99, 108-118 (1986).
27. 2 analogue and indomethacin. Br. J. Cancer, 52, 245-249 (1985).
28. Tanaka, T., Kojima, T., Okumura, A., Sugie, S. and Mori, H. Inhibitory effect of the non-steroidal anti-inflammatory drugs, indomethacin and piroxicam on 2-acetylaminofluorene-induced hepatocarcinogenesis in male ACI/N rats. Cancer Lett., 68, 111-118 (1993).
29. Hida, T., Leyton, J., Makheja, A. N., Ben-Av, P., Hla, T., Martinez, A., Mulshine, J., Malkani, S., Chung, P. and Moody, T. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs. Anticancer Res., 18, 775-782 (1998).
30. Park, K. H., Rha, S. Y., Kim, C. H., Kim, T. S., Yoo, N. C., Kim, J. H., Roh, J. K., Noh, S. H., Min, J. S., Lee, K. S., Kim, B. S. and Chung, H. C. Telomerase activity and telomere lengths in various cell lines: changes of telomerase activity can be another method for chemosensitivity evaluation. Int. J. Oncol., 13, 489-495 (1998).
31. 2 production by DTH-initiating factors. Cell Immunol., 137, 389-405 (1994).
32. Wu, J., Akaike, T. and Maeda, H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res., 58, 159-165 (1998).
33. Narisawa, T., Henmanek, P., Habs, M. and Schmael, D. Reduction of acetoxymethyl-methylnitrosamine-induced large bowel cancer in rats by indomethacin. Tohoku J. Exp. Med., 144, 237-243 (1984).
34. Rao, A. R. and Hussain, S. P. Modulation of methylanthracene-induced carcinogenesis in the uterine cervix of mouse by indomethacin. Cancer Lett., 43, 15-19 (1988).
35. Lala, P. K., Al-Mutter, N. and Orucevic, A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HeJ mice. Int. J. Cancer, 73, 371-380 (1997).